Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Author(s): Peter Hillmen, MBChB, PhD¹; Barbara Eichhorst, MD²; Jennifer R. Brown, MD, PhD³; Nicole Lamanna, MD⁴; Susan M. O’Brien, MD⁵; Constantine S. Tam, MBBS, MD^6-9; Lugui Qiu, MD, PhD¹⁰; Maciej Kazmierczak, MD, PhD¹¹; Keshu Zhou, MD, PhD¹²; Martin Šimkovič, MD, PhD13,¹⁴; Jiří Mayer, MD¹⁵; Amanda Gillespie-Twardy, MD¹⁶; Mazyar Shadman, MD, MPH^17,18; Alessandra Ferrajoli, MD¹⁹; Peter S. Ganly, BMBCh, PhD²⁰; Robert Weinkove, MBBS, PhD^21,22; Sebastian Grosicki, MD, PhD²³; Andrzej Mital, MD, PhD²⁴; Tadeusz Robak, MD, PhD²⁵; Anders Österborg, MD, PhD^26,27; Habte A. Yimer, MD²⁸; Tommi Salmi, MD²⁹; Meng Ji, MD³⁰; Jessica Yecies, PhD²⁹; Adam Idoine, PhD²⁹; Kenneth Wu, PhD²⁹; Jane Huang, MD²⁹; and Wojciech Jurczak, MD, PhD³¹

Source: DOI: 10.1200/JCO.22.00510 Journal of Clinical Oncology 41, no. 5 (February 10, 2023) 1035-1045.

Dr. Maen Hussein's Thoughts

Is ibrutininb’s days as a treatment for CLL over? Zanubrutinib is more effective and less toxic.

PURPOSE

Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve efficacy outcomes and increased BTK specificity may minimize off-target inhibition-related toxicities.

PATIENTS AND METHODS

ALPINE (ClinicalTrials.gov identifier: NCT03734016) is a global, randomized, open-label phase III study of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The primary end point was investigator-assessed overall response rate (ORR). The preplanned interim analysis was scheduled approximately 12 months after the first 415 patients were enrolled.

RESULTS

Between November 1, 2018, and December 14, 2020, 652 patients were enrolled. We present the interim analysis of the first 415 enrolled patients randomly assigned to receive zanubrutinib (n = 207) or ibrutinib (n = 208). At 15 months of median follow-up, ORR (partial or complete response) was significantly higher with zanubrutinib (78.3%; 95% CI, 72.0 to 83.7) versus ibrutinib (62.5%; 95% CI, 55.5 to 69.1; two-sided P < .001). ORR was higher with zanubrutinib versus ibrutinib in subgroups with del(17p)/TP53 mutations (80.5% v 50.0%) and del(11q) (83.6% v 69.1%); 12-month progression-free survival in all patients was higher with zanubrutinib (94.9%) versus ibrutinib (84.0%; hazard ratio, 0.40; 95% CI, 0.23 to 0.69). Atrial fibrillation rate was significantly lower with zanubrutinib versus ibrutinib (2.5% v 10.1%; two-sided P = .001). Rates of cardiac events, major hemorrhages, and adverse events leading to treatment discontinuation/death were lower with zanubrutinib.

CONCLUSION

Zanubrutinib had a significantly higher ORR, lower atrial fibrillation rate, and improved progression-free survival and overall cardiac safety profile versus ibrutinib. These data support improved efficacy/safety outcomes with selective BTK inhibition.

Author Affiliations

¹St James’s University Hospital, Leeds, United Kingdom²Department I of Internal Medicine, Center for Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Düsseldorf, Germany³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA⁴Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY⁵Chao Family Comprehensive Cancer Center, University of California, Irvine, CA⁶Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia⁷University of Melbourne, Parkville, Victoria, Australia⁸St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia⁹Royal Melbourne Hospital, Parkville, Victoria, Australia¹⁰State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China¹¹Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland¹²Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China¹³4th Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove, Czech Republic¹⁴Faculty of Medicine, Charles University, Prague, Czech Republic¹⁵Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital, Brno, Czech Republic¹⁶Blue Ridge Cancer Care, Roanoke, VA¹⁷Fred Hutchinson Cancer Research Center, Seattle, WA¹⁸Department of Medicine, University of Washington, Seattle, WA¹⁹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX²⁰Department of Haematology, Christchurch Hospital, Christchurch, New Zealand²¹Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand²²Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand²³Department of Hematology and Cancer Prevention, Health Sciences Faculty, Medical University of Silesia, Katowice, Poland²⁴Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland²⁵Medical University of Lodz, Lodz, Poland²⁶Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden²⁷Department of Hematology, Karolinska University Hospital, Stockholm, Sweden²⁸Texas Oncology-Tyler/US Oncology Research, Tyler, TX²⁹BeiGene USA, Inc, San Mateo, CA³⁰BeiGene (Beijing) Co, Ltd, Beijing, China³¹Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

For transplant-eligible patients with Mantle Cell Lymphoma, Obinutuzumab showed superior efficacy compared to Rituximab. These patients are uncommon, but the results of this study show that in this context O seems to beat R in every aspect, including a 5-yr PFS of 82.8 vs 66.6%, which is striking. I would consider this option for the appropriate patient.

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

Compelling study showing Asciminib vs. investigator’s choice TKi. Asciminib was better tolerated and with deeper molecular responses. This may become a preferred option for many new chronic myeloid leukemia (CML) patients. Cost may be an issue.

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

This combination had impressive results but led to a high rate of ventricular arrythmias (9%), hence the combination is not recommended. Another study with the combination and rituximab was also suspended, the etiology of the higher rate of Vent arrhythmias is not known. This combination in another lymphoid malignancies did not lead to that rate of toxicity.

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

Sorafenib did not help in newly diagnosed AML (with FLT-ITD) patients as maintenance therapy. MRD testing can also predict survival outcome.

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

A small number of patients in this study, but it is an interesting test to predict who can be off therapy in CML. Patients who are high risk probably should to be taken off therapy, but this gives us something to build on.